Significance of primary hyperparathyroidism in the management of osteoporosis.

[1]  J. Bilezikian,et al.  The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. , 2003, The Journal of clinical endocrinology and metabolism.

[2]  S. Silverberg,et al.  "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. , 2003, The Journal of clinical endocrinology and metabolism.

[3]  J. Bilezikian.  Bone strength in primary hyperparathyroidism , 2003, Osteoporosis International.

[4]  R. Rizzoli,et al.  Bone strength and its determinants , 2003, Osteoporosis International.

[5]  E. Eriksen.  Primary hyperparathyroidism: lessons from bone histomorphometry. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  S. Khosla,et al.  Fracture risk in primary hyperparathyroidism. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  R. Heaney.  The basis for the post-parathyroidectomy increase in bone mass. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  J. Rastad,et al.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. , 2002, The Journal of clinical endocrinology and metabolism.

[9]  A. Grey,et al.  Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. , 2002, Journal of Bone and Mineral Research.

[10]  R. Marcus.  The role of estrogens and related compounds in the management of primary hyperparathyroidism. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  D. Shoback,et al.  Calcimimetics in the treatment of primary hyperparathyroidism. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  J. Bilezikian,et al.  Bone densitometry in asymptomatic primary hyperparathyroidism. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  G. Rodan.  Bisphosphonates and primary hyperparathyroidism. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  A. Parfitt.  Parathyroid Hormone and Periosteal Bone Expansion , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[16]  E. Barrett-Connor,et al.  Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial , 2002 .

[17]  E. Seeman,et al.  Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  M. Boyanov.  Diagnostic discrepancies between two closely related forearm bone density measurement sites. , 2001, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[19]  J. Zanchetta,et al.  Raloxifene Reverses Bone Loss in Postmenopausal Women with Mild Asymptomatic Primary Hyperparathyroidism , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  P. Vestergaard,et al.  Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism , 2000, BMJ : British Medical Journal.

[21]  J. Bilezikian.  Primary hyperparathyroidism. When to observe and when to operate. , 2000, Endocrinology and metabolism clinics of North America.

[22]  G. Strewler.  Medical approaches to primary hyperparathyroidism. , 2000, Endocrinology and metabolism clinics of North America.

[23]  S. Silverberg,et al.  Parathyroid hormone. Does it have a role in the pathogenesis of osteoporosis? , 2000, Clinics in laboratory medicine.

[24]  K. Chihara,et al.  Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. , 2000, European journal of endocrinology.

[25]  E. Canalis,et al.  Skeletal growth factors. , 2000, Critical reviews in eukaryotic gene expression.

[26]  D. Dempster,et al.  The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. , 1999, The American journal of medicine.

[27]  F. Melsen,et al.  Primary hyperparathyroidism: whole-body bone mineral density in surgically treated Danish patients: a three-year follow-up study. , 1999, Bone.

[28]  E. Siris,et al.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. , 1999, The New England journal of medicine.

[29]  W. O'Fallon,et al.  Primary Hyperparathyroidism and the Risk of Fracture: A Population‐Based Study , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  S. Rudikoff,et al.  A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo1. , 1999, Endocrinology.

[31]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[32]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[33]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[34]  R. Recker,et al.  On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. , 1999, The Journal of clinical endocrinology and metabolism.

[35]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[36]  S. Adami,et al.  Bone measurements in asymptomatic primary hyperparathyroidism. , 1998, Bone.

[37]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Silverberg,et al.  Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica , 1998 .

[39]  S. Silverberg,et al.  Primary Hyperparathyroidism: Still Evolving? , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  W. O'Fallon,et al.  The Rise and Fall of Primary Hyperparathyroidism: A Population-Based Study in Rochester, Minnesota, 1965-1992 , 1997, Annals of Internal Medicine.

[41]  S. Silverberg,et al.  Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. , 1996, The Journal of clinical endocrinology and metabolism.

[42]  I. Reid,et al.  Effect of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women with Mild Primary Hyperparathyroidism , 1996, Annals of Internal Medicine.

[43]  C. Arnaud,et al.  A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  E. Siris,et al.  Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.

[45]  G. Passeri,et al.  Interleukin-11: a new cytokine critical for osteoclast development. , 1994, The Journal of clinical investigation.

[46]  R. Lindsay,et al.  Anabolic actions of parathyroid hormone on bone. , 1993, Endocrine reviews.

[47]  H. Donahue,et al.  Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin‐6 and leukemia inhibitory factor mRNA , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[48]  F. Melsen,et al.  Primary hyperparathyroidism: iliac crest cortical thickness, structure and remodeling evaluated by histomorphometric methods. Aarhus Bone and Mineral Research Group. , 1993, Bone.

[49]  W. O'Fallon,et al.  Risk of age-related fractures in patients with primary hyperparathyroidism. , 1992, Archives of internal medicine.

[50]  R. Lindsay,et al.  Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  M. Kleerekoper,et al.  Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: Clinical course and considerations bearing on the need for surgical intervention , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  B. Hasegawa,et al.  Effect of bone distribution on vertebral strength: assessment with patient-specific nonlinear finite element analysis. , 1991, Radiology.

[53]  R. Lindsay,et al.  The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. , 1990, The Journal of clinical endocrinology and metabolism.

[54]  J. Nordenström,et al.  Skeletal remineralization after surgery for primary and secondary hyperparathyroidism. , 1990, Surgery.

[55]  T. Clemens,et al.  Skeletal disease in primary hyperparathyroidism , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[56]  M. Kleerekoper,et al.  Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. , 1988, The Journal of clinical endocrinology and metabolism.

[57]  S. Stanbury,et al.  Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. , 1974, The American journal of medicine.

[58]  J. Gallagher,et al.  The effect of ethinyloestradiol on calcium and phosphorus metabolism of post-menopausal women with primary hyperparathyroidism. , 1973, Clinical science and molecular medicine.

[59]  S. Rockoff,et al.  The relative contribution of trabecular and cortical bone to the strength of human lumbar vertebrae , 2005, Calcified Tissue Research.

[60]  M. Hahn,et al.  Trabecular bone structure in patients with primary hyperparathyroidism , 2004, Virchows Archiv.

[61]  G. Rodan,et al.  The role of integrins in osteoclast function , 1999, Journal of Bone and Mineral Metabolism.

[62]  C. Rosen,et al.  The insulin-like growth factors: Potential anabolic agents for the skeleton , 1998 .

[63]  M. Brennan,et al.  NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. , 1991, Annals of internal medicine.